Trial Profile
Z 31702 - Improving Pregnancy Outcomes With Progesterone (IPOP): a Trial of 17-Hydroxyprogesterone Caproate to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Hydroxyprogesterone (Primary)
- Indications Preterm labour
- Focus Therapeutic Use
- Acronyms IPOP
- 10 Mar 2021 Results of secondary analysis evaluating whether the risk of preeclampsia associated with PI-based ART and whether hydroxyprogesterone modified this risk, presented at the 28th Conference on Retroviruses and Opportunistic Infections
- 25 Sep 2020 Status changed from active, no longer recruiting to completed.
- 25 Mar 2020 Planned End Date changed from 1 Dec 2020 to 1 Sep 2020.